perampanel
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Partial Seizures
Conditions
Refractory Partial Seizures
Trial Timeline
Jun 17, 2009 → Oct 31, 2016
NCT ID
NCT00903786About perampanel
perampanel is a phase 2 stage product being developed by Eisai for Refractory Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00903786. Target conditions include Refractory Partial Seizures.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Partial Seizures were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01871233 | Pre-clinical | Completed |
| NCT02307578 | Pre-clinical | Completed |
| NCT05533814 | Approved | Completed |
| NCT04252846 | Pre-clinical | Completed |
| NCT03836924 | Pre-clinical | Completed |
| NCT03424564 | Phase 1 | Completed |
| NCT03288129 | Approved | Completed |
| NCT02914314 | Phase 2 | Completed |
| NCT02849626 | Phase 3 | Completed |
| NCT02726074 | Approved | Completed |
| NCT04230044 | Pre-clinical | Completed |
| NCT04257604 | Pre-clinical | Completed |
| NCT02727101 | Approved | Terminated |
| NCT02427607 | Phase 3 | Completed |
| NCT02279485 | Phase 1 | Completed |
| NCT02033902 | Pre-clinical | Completed |
| NCT01527006 | Phase 2 | Completed |
| NCT00903786 | Phase 2 | Completed |
| NCT00735397 | Phase 3 | Completed |
| NCT00505622 | Phase 3 | Terminated |
Competing Products
20 competing products in Refractory Partial Seizures